- $1.06bn
- $951.49m
- $89.06m
CeriBell, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ceribell Q2 revenue beats estimates; raises 2026 revenue outlook
Ceribell beats Q1 revenue estimates; lifts 2026 guidance
Ceribell beats Q4 revenue expectations
Brief: Ceribell Receives FDA Breakthrough Device Designation For Lvo Stroke Detection
Ceribell jumps on FDA clearance of brain monitoring device
U.S. RESEARCH ROUNDUP-ADM, Pinterest, Ul Solutions
Brief: Ceribell Says Everwin China & Everwin Precision Technology Entered Third Amendment
U.S. RESEARCH ROUNDUP-Allstate, BP, Oracle
CeriBell Inc reports results for the quarter ended June 30 - Earnings Summary
CeriBell Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ceribell Files Complaints Against Natus For Patent Infringement
CeriBell Inc reports results for the quarter ended March 31 - Earnings Summary
CeriBell Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Ceribell Says EEG System Receives FedRAMP High Authorization
Brief: FDA Clears Ceribell’S Clarity Algorithm For Pediatric Patients
CeriBell Inc reports results for the quarter ended December 31 - Earnings Summary
CeriBell Inc expected to post a loss of 32 cents a share - Earnings Preview
Beta Bionics targets up to $616 mln valuation in US IPO (updated)